Prostate Cancer and Prostatic Diseases

Papers
(The H4-Index of Prostate Cancer and Prostatic Diseases is 26. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2020-03-01 to 2024-03-01.)
ArticleCitations
How to turn up the heat on the cold immune microenvironment of metastatic prostate cancer92
Clinical utility of the exosome based ExoDx Prostate(IntelliScore) EPI test in men presenting for initial Biopsy with a PSA 2–10 ng/mL91
Cancer detection rates of the PI-RADSv2.1 assessment categories: systematic review and meta-analysis on lesion level and patient level53
Depression, anxiety, and suicidality in patients with prostate cancer: a systematic review and meta-analysis of observational studies48
A systematic review and meta-analysis of the diagnostic accuracy of biparametric prostate MRI for prostate cancer in men at risk46
Advances in PSMA-targeted therapy for prostate cancer46
The promising role of new molecular biomarkers in prostate cancer: from coding and non-coding genes to artificial intelligence approaches43
Clinical use of the SelectMDx urinary-biomarker test with or without mpMRI in prostate cancer diagnosis: a prospective, multicenter study in biopsy-naïve men38
High-intensity interval training produces a significant improvement in fitness in less than 31 days before surgery for urological cancer: a randomised control trial37
Evolving role of 225Ac-PSMA radioligand therapy in metastatic castration-resistant prostate cancer—a systematic review and meta-analysis36
Predicting high-grade prostate cancer at initial biopsy: clinical performance of the ExoDx (EPI) Prostate Intelliscore test in three independent prospective studies35
Management of prostate cancer patients during COVID-19 pandemic35
Evaluating F-18-PSMA-1007-PET in primary prostate cancer and comparing it to multi-parametric MRI and histopathology35
Phase 2 trial of monoamine oxidase inhibitor phenelzine in biochemical recurrent prostate cancer33
3-Year results following treatment with the second generation of the temporary implantable nitinol device in men with LUTS secondary to benign prostatic obstruction33
Treatment of nonmetastatic castration-resistant prostate cancer: focus on second-generation androgen receptor inhibitors33
PARP inhibitors as a new therapeutic option in metastatic prostate cancer: a systematic review33
Racial disparities in prostate cancer among black men: epidemiology and outcomes32
Androgen receptor variant-driven prostate cancer II: advances in laboratory investigations31
Crosstalk between COVID-19 and prostate cancer31
Androgen receptor gain in circulating free DNA and splicing variant 7 in exosomes predict clinical outcome in CRPC patients treated with abiraterone and enzalutamide31
A pilot window-of-opportunity study of preoperative fluvastatin in localized prostate cancer30
The expression of YAP1 is increased in high-grade prostatic adenocarcinoma but is reduced in neuroendocrine prostate cancer28
Overall survival and adverse events after treatment with darolutamide vs. apalutamide vs. enzalutamide for high-risk non-metastatic castration-resistant prostate cancer: a systematic review and networ27
Clinical considerations for the management of androgen indifferent prostate cancer27
Exercise modulation of tumour perfusion and hypoxia to improve radiotherapy response in prostate cancer26
Survival outcomes in patients with chemotherapy-naive metastatic castration-resistant prostate cancer treated with enzalutamide or abiraterone acetate26
0.027454137802124